Patents by Inventor Michael E. Mertzman

Michael E. Mertzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20240109888
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: July 6, 2023
    Publication date: April 4, 2024
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael E. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA
    Publication number: 20230020273
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: October 28, 2019
    Publication date: January 19, 2023
    Inventors: Steven H. Spergel, William J. Pitts, Michael E. Mertzman, Ryan M. Moslin, Trevor C. Sherwood, John L. Gilmore, Alaric J. Dyckman
  • AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS
    Publication number: 20220315580
    Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: December 9, 2020
    Publication date: October 6, 2022
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Aminoimidazopyridazines as kinase inhibitors
    Patent number: 11440913
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 13, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael E. Mertzman, Carolyn Diane Dzierba, Jason M. Guernon, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Steven H. Spergel
  • Aminotriazolopyridines as kinase inhibitors
    Patent number: 10913738
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
    Patent number: 10836770
    Abstract: Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of formula I are useful for the treatment of inflammatory or autoimmune diseases.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: November 17, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Steven H. Spergel, Michael E. Mertzman
  • AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS
    Publication number: 20200277296
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 29, 2018
    Publication date: September 3, 2020
    Inventors: Michael E. Mertzman, Carolyn Diane Dzierba, Jason M. Guernon, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Steven H. Spergel
  • AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS
    Publication number: 20190389859
    Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: February 12, 2018
    Publication date: December 26, 2019
    Inventors: Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
  • IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20190225620
    Abstract: Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of formula I are useful for the treatment of inflammatory or autoimmune diseases.
    Type: Application
    Filed: October 2, 2017
    Publication date: July 25, 2019
    Inventors: Steven H. Spergel, Michael E. Mertzman
  • Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9987266
    Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: June 5, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES
    Publication number: 20170209426
    Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 27, 2017
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9663467
    Abstract: Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: May 30, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman, Chunjian Liu
  • ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES
    Publication number: 20160280649
    Abstract: Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: January 16, 2014
    Publication date: September 29, 2016
    Inventors: Ryan M. MOSLIN, David S. WEINSTEIN, Stephen T. WROBLESKI, Yanlei ZHANG, John S. TOKARSKI, Michael E. MERTZMAN, Chunjian LIU
  • Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9315494
    Abstract: Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: April 19, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, Shuqun Lin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman
  • ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20150307483
    Abstract: Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 29, 2015
    Inventors: Ryan M. Moslin, Shuqun Lin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman
  • Aryl pyridines and methods of their use
    Patent number: 8153804
    Abstract: Aryl pyridines, compositions comprising them, and methods of their use for the treatment, prevention and management of a variety of diseases and disorders are disclosed.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: April 10, 2012
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: David J. Augeri, James E. Tarver, Jr., Qinghong Fu, Michael Victor Voronkov, Doan Hackley, Michael E. Mertzman, Marianne Carlsen
  • Laxative composition
    Publication number: 20020071872
    Abstract: The present invention provides a composition comprising a) a laxative selected from the group consisting of bisacodyl and enteric coated vanilloid compounds; and b) simethicone in an amount effective to enhance the efficacy of the laxative. The simethicone enhances the transit of the laxatives through the small bowel.
    Type: Application
    Filed: August 8, 2001
    Publication date: June 13, 2002
    Inventors: Gerard P. McNally, Charles E. Pendley, Brid T. Burruano, Nancy B. Rainey, Steven A. Jacobs, Shun Por Li, Michael E. Mertzman, David W. Wynn, Anthony J. Le Storti